Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma


Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform therapy called Tumor Treating Fields, and Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage

Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil

ICON plc to Present at UBS Virtual Global Healthcare Conference
ICON plc to Present at UBS Virtual Global Healthcare Conference


ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr

New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program
New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program


Pfizer Inc. (NYSE: PFE) today announced that new data from clinical trials of 18 approved and investigational medicines will be presented virtually at the ASCO20 Virtual Scientific Program, from

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the RBC Capital Markets

Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference
Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Bank of America 2020 Health Care Conference on Thursday, May 14 at 4:20

CymaBay: April-Empfehlung mit +196% Kursgewinn!
CymaBay: April-Empfehlung mit +196% Kursgewinn!

Die Party im No Brainer Club kennt derzeit wieder keine Grenzen. Mit CymaBay Therapeutics (WKN: A116DD) ist der nächste Vervielfacher eingetütet – in kaum mehr als einem Monat!

Die NBC-Experten

Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results
Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights.



“I’m proud of how the Sangamo team has

Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK®
Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK®


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to

NanoRepro: Nicht mehr als eine Push-News!
NanoRepro: Nicht mehr als eine Push-News!

NanoRepro (WKN: 657710) meldet die Auslieferung seines Covid-19-Schnelltests. Die Zocker-Aktie springt mal wieder in die Höhe. Doch auch diesmal gilt: Die Chance sollte zum Ausstieg genutzt werden!

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Gilead Sciences: Remdesivir ist leider kein Allheilmittel
Gilead Sciences: Remdesivir ist leider kein Allheilmittel

Gilead Sciences (WKN: 885823) ist, langfristig betrachtet, eine der größten Erfolgsgeschichten im Biotechsektor. So gelang es dem, zwischenzeitlich zu einem Konzern herangewachsenen, Unternehmen

Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting
Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, May 15, 2020 at 10:00 a.m. EDT. The purpose

Savara Announces Change of Date for 2020 Annual Meeting of Stockholders
Savara Announces Change of Date for 2020 Annual Meeting of Stockholders


Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced a change in the date, time, and format of its 2020 Annual Meeting of Stockholders due to public health and safety

Biotest: Corona-Ambitionen intensiviert!
Biotest: Corona-Ambitionen intensiviert!

Biotest (WKN: 522723) verstärkt seine medizinischen Ambitionen gegen COVID-19. Dazu präsentierte das Unternehmen heute seine Pläne ebenso wie die Q1-Zahlen.

Die Umsatzerlöse in den ersten drei

Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting
Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and

Puma Biotechnology Reports First Quarter 2020 Financial Results
Puma Biotechnology Reports First Quarter 2020 Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2020. Unless otherwise stated, all comparisons are for the

Savara Reports First Quarter 2020 Financial Results and Provides Business Update
Savara Reports First Quarter 2020 Financial Results and Provides Business Update


Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the first quarter ending March 31, 2020 and provided a business update.



“With the recent clarity

Xencor Reports First Quarter 2020 Financial Results
Xencor Reports First Quarter 2020 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial

IMV Inc. Announces Closing of $25.1 Million Private Placement
IMV Inc. Announces Closing of $25.1 Million Private Placement


IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious

Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner CANbridge Pharmaceuticals, Inc. has received marketing approval of NERLYNX® (neratinib) in

Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update
Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Charles River Laboratories Announces First-Quarter 2020 Results
Charles River Laboratories Announces First-Quarter 2020 Results


Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2020. For the quarter, revenue was $707.1 million, an increase of 17.0% from $604.6

Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020
Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that it will release its first quarter 2020 financial results on Thursday, May 14, 2020, after the markets

QIAGEN meldet vollständige Ergebnisse für das erste Quartal 2020
QIAGEN meldet vollständige Ergebnisse für das erste Quartal 2020


QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) gab heute die vollständigen Ergebnisse der operativen Tätigkeit für das erste Quartal 2020 bekannt, wobei der Konzernumsatz und der bereinigte